Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page - v8 N2 N" y( ]/ I
; k; Z2 `. ~( W" l& V w; U
' Q' b* J* e5 I- R! LSub-category:3 d) J% ]6 X$ D
Molecular Targets
8 d x6 Q+ K! m6 O6 g; U5 C- f" J
$ c* r, t* D1 _. U4 s
' {, y% ^8 I+ G7 G2 q8 p" N' hCategory:
9 ]8 M- G. l& h5 cTumor Biology
* M- v, n1 Z# o! f! ?0 W5 L4 k0 j! w9 K7 }& T+ F1 o
* d) L1 j9 m( g* ^! v2 g) ]
Meeting:* H# D+ b3 `9 Q
2011 ASCO Annual Meeting
( |( u0 w0 H" l g W& |9 m0 ^9 |4 J, |/ A: X
1 R) M/ t3 o1 m
Session Type and Session Title:
; Z* T! T' W- A0 \Poster Discussion Session, Tumor Biology 2 L4 }' T) H8 `/ Z9 Q
! E7 L" m( F' r* ]( y- s8 U8 f. N6 D2 [$ Y/ ~! h4 ?
Abstract No:; X @1 S0 z0 R
10517 ( L% o2 E( l6 f0 G
6 \- b5 h7 k2 r0 Z0 N- N5 e" n5 q6 N' a
Citation:& r$ ?- z3 ?5 ~2 i9 [# S$ M
J Clin Oncol 29: 2011 (suppl; abstr 10517)
$ S! p" J. s* I" r* G- I: h y
5 i2 L: g) a! n" A& I* |9 Q
0 I- C3 |+ ^ f# e2 u3 F4 J4 gAuthor(s):
$ j1 k1 R- ~3 x8 q& H5 NJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ! O8 D$ e9 g( i
. ^* Q1 D7 G2 M: A! h4 |' ]
9 f. L+ b1 A3 P% K d+ O' q
0 s9 \! O3 T. ]: ~8 EAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
- j) _) m% u& a0 V. u8 R3 L+ }( U
Abstract Disclosures
9 c7 y' }8 a" c4 Q$ l9 c
) C! W, t) P* M4 V4 X( B X% f2 oAbstract:
, W' g( F3 ^7 H0 M# R
& \: W0 b! x+ c* R) o
) r, z1 Q# d$ s* xBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
. b& |. n; \( C" F' a$ \+ Z5 c1 _8 L1 R {1 h
% [: U7 V) q q& k% X8 v
|
显身卡
